新型冠状病毒感染对哮喘儿童肺功能影响

doi:10.12372/jcp.2022.23e0163

摘要/Abstract

摘要：

COVID-19的流行使儿童哮喘的管理受到了新的挑战。文章从分子机制到病理改变，分析哮喘儿童气道损伤，探讨新型冠状病毒对肺功能的影响，以为临床医师在新冠疫情背景下儿童哮喘的诊治提供参考。

Abstract:

The pandemic of COVID-19 raises new challenges in the management of pediatric asthma. We analyzed airway injury in children with asthma from molecular mechanism to pathological alterations and explored the effect of SARS-CoV-2 on pulmonary function, which will inform clinicians in the diagnosis and management of childhood asthma in the context of the new coronavirus epidemic.

Key words: respiratory virus, SARS-CoV-2, lung function, bronchial asthma, child

王金荣, 苗瑜, 光增, 曹洛菲. 新型冠状病毒感染对哮喘儿童肺功能影响[J]. 临床儿科杂志, 2023, 41(5): 333-338.

WANG Jinrong, MIAO Yu, MA Guangzeng, CAO Luofei. Effect of SARS-CoV-2 infection on pulmonary function in children with asthma[J]. Journal of Clinical Pediatrics, 2023, 41(5): 333-338.

参考文献 44

[1]	World Health Organization. WHO Coronavirus (COVID-19)[EB/OL]. [2022-02-25]. https://covid19.who.int.
[2]	No authors listed. The global asthma report 2022[J]. Int J Tuberc Lung Dis, 2022, 26(1): 1-104.
[3]	Campos C, Prokopich S, Loewen H, et al. Long-term effect of COVID-19 on lung imaging and function, cardiorespiratory symptoms, fatigue, exercise capacity, and functional capacity in children and adolescents: a systematic review and meta-analysis[J]. Healthcare (Basel), 2022, 10(12): 2492.
[4]	Seibold MA, Moore CM, Everman JL, et al. Risk factors for SARS-CoV-2 infection and transmission in households with children with asthma and allergy: a prospective surveillance study[J]. J Allergy Clin Immunol, 2022, 150(2): 302-311. doi: 10.1016/j.jaci.2022.05.014 pmid: 35660376
[5]	Kompaniyets L, Agathis NT, Nelson JM, et al. Underlying medical conditions associated with severe COVID-19 illness among children[J]. JAMA Netw Open, 2021, 4(6): e2111182. doi: 10.1001/jamanetworkopen.2021.11182
[6]	Shi T, Pan J, Katikireddi SV, et al. Risk of COVID-19 hospital admission among children aged 5-17 years with asthma in Scotland: a national incident cohort study[J]. Lancet Respir Med, 2022, 10: 191-198. doi: 10.1016/S2213-2600(21)00491-4
[7]	Chiang CY, Ellwood P, Ellwood E, et al. Infection with SARS-CoV-2 among children with asthma: evidence from Global Asthma Network[J]. Pediatr Allergy Immunol, 2022, 33(1): e13709.
[8]	Pivniouk V, Pivniouk O, DeVries A, et al. The OM-85 bacterial lysate inhibits SARS-CoV-2 infection of epithelial cells by downregulating SARS-CoV-2 receptor expression[J]. J Allergy Clin Immunol, 2022, 149(3): 923-933.. doi: 10.1016/j.jaci.2021.11.019
[9]	Tay MZ, Poh CM, Rénia L, et al. The trinity of COVID-19: immunity, inflammation and intervention[J]. Nat Rev Immunol, 2020, 20(6): 363-374. doi: 10.1038/s41577-020-0311-8 pmid: 32346093
[10]	Vora SM, Lieberman J, Wu H. Inflammasome activation at the crux of severe COVID-19[J]. Nat Rev Immunol, 2021, 21(11): 694-703. doi: 10.1038/s41577-021-00588-x pmid: 34373622
[11]	Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet (London, England), 2020, 395(10223): 497-506. doi: 10.1016/S0140-6736(20)30183-5
[12]	Shoenfeld Y. Corona (COVID-19) time musings: our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning[J]. Autoimmun Rev, 2020, 19(6): 102538. doi: 10.1016/j.autrev.2020.102538
[13]	Zhao L, Zhang YP, Yang X, et al. Eosinopenia is associated with greater severity in patients with coronavirus disease 2019[J]. Allergy, 2021, 76: 562-564. doi: 10.1111/all.v76.2
[14]	Crook H, Raza S, Nowell J, et al. Long covid-mechanisms, risk factors, and management[J]. BMJ, 2021, 374: n1648.
[15]	Cui S, Chen S, Li X, et al. Prevalence of venous throm-boembolism in patients with severe novel coronavirus pneumonia[J]. J Thromb Haemost, 2020, 18(6): 1421-1424. doi: 10.1111/jth.14830
[16]	Torres-Castro R, Vasconcello-Castillo L, Alsina-Restoy X, et al. Respiratory function in patients post-infection by COVID-19: a systematic review and meta-analysis[J]. Pulmonology, 2021, 27: 328-337. doi: 10.1016/j.pulmoe.2020.10.013
[17]	Öztürk GK, Beken B, Doğan S, et al. Pulmonary function tests in the follow-up of children with COVID-19[J]. Eur J Pediatr, 2022, 181: 2839-2847. doi: 10.1007/s00431-022-04493-w pmid: 35522314
[18]	Soyak Aytekin E, Sahiner UM, Tuten Dal S, et al. Obesity is a risk factor for decrease in lung function after COVID-19 infection in children with asthma[J]. Pediatr Pulmonol, 2022, 57: 1668-1676. doi: 10.1002/ppul.v57.7
[19]	Choudhary S, Sharma K, Silakari O. The interplay between inflammatory pathways and COVID-19: a critical review on pathogenesis and therapeutic options[J]. Microb Pathog, 2021, 150: 104673. doi: 10.1016/j.micpath.2020.104673
[20]	D'Agnillo F, Walters KA, Xiao Y, et al. Lung epithelial and endothelial damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in fatal COVID-19[J]. Sci Transl Med, 2021, 13: eabj7790. doi: 10.1126/scitranslmed.abj7790
[21]	Du X, Yang Y, Yang Mg et al. ITGB4 deficiency induces mucus hypersecretion by upregulating MUC5AC in RSV-infected airway epithelial cells[J]. Int J Biol Sci, 2022, 18: 349-359. doi: 10.7150/ijbs.66215 pmid: 34975337
[22]	Sajuthi SP, DeFord P, Li Y, et al. Type 2 and interferon inflammation regulate SARS-CoV-2 entry factor expression in the airway epithelium[J]. Nat Commun, 2020, 11(1): 5139. doi: 10.1038/s41467-020-18781-2 pmid: 33046696
[23]	Postma DS, Brightling C, Baldi S, et al. Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study[J]. Lancet Respir Med, 2019, 7(5): 402-416. doi: 10.1016/S2213-2600(19)30049-9 pmid: 30876830
[24]	Ashkenazi-Hoffnung L, Shmueli E, Ehrlich S, et al. Long COVID in children: observations from a designated pediatric clinic[J]. Pediatr Infect Dis J, 2021, 40: e509-e511. doi: 10.1097/INF.0000000000003285 pmid: 34371507
[25]	Maniscalco M, Ambrosino P, Fuschillo S, et al. Bronchodilator reversibility testing in post-COVID-19 patients undergoing pulmonary rehabilitation[J]. Respir Med, 2021, 182: 106401. doi: 10.1016/j.rmed.2021.106401
[26]	Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J]. Lancet Respir Med, 2020, 8(4): 420-422. doi: 10.1016/S2213-2600(20)30076-X pmid: 32085846
[27]	国家儿童医学中心, 首都医科大学附属北京儿童医院新型冠状病毒感染重症救治专家组, 北京儿童新型冠状病毒感染医疗救治市级专家组. 儿童新型冠状病毒Omicron变异株感染重症早期识别和诊治建议[J]. 中华儿科杂志, 2023, 61(3): 199-202.
[28]	Faverio P, Luppi F, Rebora P, et al. Six-month pulmonary impairment after severe COVID-19: a prospective, multicentre follow-up study[J]. Respiration, 2021, 100: 1078-1087. doi: 10.1159/000518141
[29]	Xu C, Ma M, Yi Y, et al. Clinical features and high-resolution chest computerized tomography findings of children infected by the B.1.617.2 variant of coronavirus disease 2019[J]. Ann Med, 2022, 54(1): 2391-2401. doi: 10.1080/07853890.2022.2114608 pmid: 36039499
[30]	Long ME, Mallampalli RK, Horowitz JC. Pathogenesis of pneumonia and acute lung injury[J]. Clin Sci (Lond), 2022, 136(10): 747-769. doi: 10.1042/CS20210879 pmid: 35621124
[31]	Heiss R, Tan L, Schmidt S, et al. Pulmonary dysfunction after pediatric COVID-19[J]. Radiology, 2023, 306(3): e221250. doi: 10.1148/radiol.221250
[32]	Camporota L, Cronin JN, Busana M, et al. Pathophysiology of coronavirus-19 disease acute lung injury[J]. Curr Opin Crit Care e, 2022, 28(1): 9-16.
[33]	Xiao C, Puddicombe SM, Field S, et al. Defective epithelial barrier function in asthma[J]. J Allergy Clin Immunol, 2011, 128(3): 549-556. doi: 10.1016/j.jaci.2011.05.038 pmid: 21752437
[34]	Bajbouj K, Ramakrishnan RK, Hamid Q. Role of matrix metalloproteinases in angiogenesis and its implications in asthma[J]. J Immunol Res, 2021: 6645072.
[35]	Lee KS, Min KH, Kim SR, et al. Vascular endothelial growth factor modulates matrix metalloproteinase-9 expression in asthma[J]. Am J Respir Crit Care Med, 2006, 174(2): 161-170. doi: 10.1164/rccm.200510-1558OC
[36]	Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19[J]. Nature, 2020, 584(7821): 463-469. doi: 10.1038/s41586-020-2588-y
[37]	Pathinayake PS, Awatade NT, Wark PAB. Type 2 immunity and its impact on COVID-19 infection in the airways[J]. Viruses, 2023, 15(2): 402. doi: 10.3390/v15020402
[38]	Roberts LM, Jessop F, Wehrly TD, et al. CuttinG EDGE: LUNG-RESident T cells elicited by SARS-CoV-2 do not mediate protection against secondary infection[J]. J Immunol, 2021, 207(10): 2399-404. doi: 10.4049/jimmunol.2100608 pmid: 34607940
[39]	Rahimi RA, Nepal K, Cetinbas M, et al. Distinct functions of tissue-resident and circulating memory Th2 cells in allergic airway disease[J]. J Exp Med, 2020, 217(9) : e20190865.
[40]	May BC, Gallivan KH. Levocetirizine and montelukast in the COVID-19 treatment paradigm[J]. Int Immu-nopharmacol, 2022, 103: 108412.
[41]	Mera-Cordero F, Bonet-Monne S, Almeda-Ortega J, et al. Double-blind placebo-controlled randomized clinical trial to assess the efficacy of montelukast in mild to moderate respiratory symptoms of patients with long COVID: E-SPERANZA COVID Project study protocol[J]. Trials, 2022, 23(1): 19. doi: 10.1186/s13063-021-05951-w pmid: 34991703
[42]	Zhang L, Wang X, Huang Y, et al. Pediatric asthma situation in Chengdu, China, during the COVID-19 pandemic: an observational study[J]. J Asthma Allergy, 2021, 14: 829-838. doi: 10.2147/JAA.S315695 pmid: 34276218
[43]	Borg Bm, Osadnik C, Adam K, et al. Pulmonary function testing during SARS-CoV-2: An ANZSRS/TSANZ position statement[J]. Respirology, 2022, 27(9): 688-719. doi: 10.1111/resp.14340 pmid: 35981737
[44]	Franczuk M, Przybyłowski T, Czajkowska-Malinowska M, et al. Spirometry during the SARS-CoV-2 pandemic. Guidelines and practical advice from the expert panel of Respiratory Physiopathology Assembly of Polish Respiratory Society[J]. Adv Respir Med, 2020, 88(6): 640-650. doi: 10.5603/ARM.a2020.0186 pmid: 33393664